WO2003013498A3 - Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen - Google Patents

Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen Download PDF

Info

Publication number
WO2003013498A3
WO2003013498A3 PCT/DE2002/002666 DE0202666W WO03013498A3 WO 2003013498 A3 WO2003013498 A3 WO 2003013498A3 DE 0202666 W DE0202666 W DE 0202666W WO 03013498 A3 WO03013498 A3 WO 03013498A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cyclodextrin complexes
nitrate ester
particularly coronary
treating diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/002666
Other languages
English (en)
French (fr)
Other versions
WO2003013498A2 (de
Inventor
Walter Heinzelmann
Stephan Bojar
Cornelius Ruloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynamit Nobel GmbH
Original Assignee
Dynamit Nobel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamit Nobel GmbH filed Critical Dynamit Nobel GmbH
Priority to JP2003518507A priority Critical patent/JP2004536888A/ja
Priority to AU2002331527A priority patent/AU2002331527A1/en
Priority to HU0401424A priority patent/HUP0401424A3/hu
Priority to US10/483,219 priority patent/US20040198698A1/en
Priority to PL02365225A priority patent/PL365225A1/xx
Priority to EP02767047A priority patent/EP1411915A2/de
Publication of WO2003013498A2 publication Critical patent/WO2003013498A2/de
Publication of WO2003013498A3 publication Critical patent/WO2003013498A3/de
Anticipated expiration legal-status Critical
Priority to US11/973,780 priority patent/US20080091006A1/en
Ceased legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung beschreibt 1:1-Komplexe von organischen Nitratestern mit Cyclodextrinen, die Herstellung dieser Komplexe und Verwendung derselben in der Koronarmedizin.
PCT/DE2002/002666 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen Ceased WO2003013498A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2003518507A JP2004536888A (ja) 2001-07-20 2002-07-19 硝酸エステル−シクロデキストリン錯体
AU2002331527A AU2002331527A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
HU0401424A HUP0401424A3 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes
US10/483,219 US20040198698A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes
PL02365225A PL365225A1 (en) 2001-07-20 2002-07-19 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
EP02767047A EP1411915A2 (de) 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen, insbesondere koronarerkrankungen
US11/973,780 US20080091006A1 (en) 2001-07-20 2007-10-10 Nitrate ester cyclodextrin complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134683 2001-07-20
DE10134683.2 2001-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/973,780 Continuation US20080091006A1 (en) 2001-07-20 2007-10-10 Nitrate ester cyclodextrin complexes

Publications (2)

Publication Number Publication Date
WO2003013498A2 WO2003013498A2 (de) 2003-02-20
WO2003013498A3 true WO2003013498A3 (de) 2003-05-22

Family

ID=7692053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/002666 Ceased WO2003013498A2 (de) 2001-07-20 2002-07-19 Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen

Country Status (7)

Country Link
US (2) US20040198698A1 (de)
EP (1) EP1411915A2 (de)
JP (1) JP2004536888A (de)
AU (1) AU2002331527A1 (de)
HU (1) HUP0401424A3 (de)
PL (1) PL365225A1 (de)
WO (1) WO2003013498A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073931A (en) * 1974-03-27 1978-02-14 Teijin Limited Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMICAL ABSTRACT [online] 28 February 1986 (1986-02-28), RICHTER, GEDEON, VEGYESZETI GYAR RT., HUNG.: "Preparation of the complex of isosorbide 2,5-dinitrate cyclodextrin as coronary vasodilator", XP002225618, Database accession no. 106:143984 CA *
DATABASE CHEMICAL ABSTRACT [online] 28 June 1980 (1980-06-28), CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT., HUNG.: "Explosion-proof, tabletable .beta.-cyclodextrin nitroglycerin complexes", XP002225619, Database accession no. 94:162749 CA *
STADLER-SZOKE, AGNES ET AL: "Inclusion complex of nitroglycerin -.beta.-cyclodextrin", ACTA PHARMACEUTICA HUNGARICA (1979), 49(1), 30-4, 1979, XP009002665 *

Also Published As

Publication number Publication date
WO2003013498A2 (de) 2003-02-20
HUP0401424A2 (hu) 2004-11-29
PL365225A1 (en) 2004-12-27
EP1411915A2 (de) 2004-04-28
JP2004536888A (ja) 2004-12-09
AU2002331527A1 (en) 2003-02-24
US20040198698A1 (en) 2004-10-07
US20080091006A1 (en) 2008-04-17
HUP0401424A3 (en) 2008-03-28

Similar Documents

Publication Publication Date Title
WO2002047668A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und ciclesonide
WO2002008190A3 (de) Neue heteroaryl-derivate und deren verwendung als antitumormittel
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
YU31801A (sh) Amidi antranilne kiseline i njihova upotreba kao leka
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004071382A3 (en) Substituted heterocycles
WO2003080582A3 (de) Fredericamycin-derivate
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
HUT68589A (en) The cyclodextrin cluster complexes of taxol, taxotere, or taxus, process for their production, and use of them
WO2001051044A3 (en) Substances for use in treating psoriasis
EP1589115A3 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
MXPA03008186A (es) Amidas de acidos carboxilicos antitromboticas, su preparacion y su uso como medicamentos.
EA201070193A1 (ru) Лечение детских опухолей
WO2003013498A3 (de) Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen insbesondere koronarerkrankungen
WO2003024996A3 (de) Antibakterielle makrozyklen
MY138088A (en) Use of deoxypeganine for treating clinical depression
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
WO2000069841A3 (en) Benzofuranylaminoalcohols
WO2004037278A3 (de) Dyslokalisationsmoleküle und deren verwendung
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BR BY BZ CA CH CN CO CR CU CZ DE DK DZ EC EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003518507

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002767047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10483219

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002767047

Country of ref document: EP